Thank you for joining.
The presentation will start at 4:00PM ET.
There is no audio being transmitted at this time.
Audio is provided via your computer speakers, please check your settings.

2020 General Business Meeting

Presented at Virtual ISPOR 2020

June 10, 2020
2020 General Business Meeting

Presented at Virtual ISPOR 2020

June 10, 2020
President’s Remarks

Nancy Devlin, PhD
President
ISPOR
Antitrust Compliance Statement

- ISPOR has a policy of strict compliance with both United States, and other applicable international antitrust laws and regulations.

- Antitrust laws prohibit competitors from engaging in actions that could result in an unreasonable restraint of trade.

- ISPOR members must avoid discussing certain topics when they are together, including, prices, fees, rates, profit margins, or other terms or conditions of sale.

- Members have an obligation to terminate any discussion, seek legal counsel’s advice, or, if necessary, terminate any meeting if the discussion might be construed to raise antitrust risks.

- The Antitrust policy is available on the ISPOR website.
Today’s Discussion

• **Call to Order and President’s Report**—Nancy Devlin, PhD, 2019-2020 President

• **CEO’s Report, including Financial and Audit Committee Report** — Nancy S. Berg, CEO and Executive Director

• **ISPOR Publications Reports**
  - *Value in Health* Editors-in-Chief Report—C. Daniel Mullins, PhD
  - *Value in Health Regional Issues* Co-Editor-in-Chief Report—Manuel Espinoza, MD, MSc, PhD
  - *Value & Outcomes Spotlight* Editor-in-Chief Report—David Thompson, PhD

• **Member Open Discussion**—ISPOR Members

• **Adjournment**—Nancy Devlin
Motion from ISPOR Members

As per Article XI, Section 1 of the Society's Bylaws:

Any member of the Society who is in good standing may submit a motion for consideration by the members as a whole or by the Board of Directors. All such motions must be submitted in writing to the CEO & Executive Director at least 48 hours prior to the General Meeting, unless notice is waived by the President. Motions presented at the General Business Meeting will be submitted to the Board of Directors for consideration.

Motion submitted by Dr Junling Wang asking the Board to consider establishing a subgroup for academic members, those interested in working in academia, postdocs, and early stage faculty members.
2019-2020 Board of Directors—Thank You!

President (2019-2020)
Nancy J. Devlin, PhD

President-Elect (2019-2020)
Jens Grueger, PhD

Past President (2019-2020)
Federico Augusto ski, MD, MSc, PhD

Director (2017-2020)
Meindert Boysen, PharmD

Director (2016-2021)
Jalpa A. Doshi, PhD

Director (2017-2020)
Stephanie R. Earnshaw, PhD

Director (2017-2020)
Jan Elias Hansen, PhD

Director (2018-2021)
Neil Hawkins, MSc, MBA, PhD

Director (2018-2021)
Rok Hren, PhD, MSc

Director (2018-2021)
Raoh-Fang (Jasmine) Pwu, PhD

Treasurer (2017-2020)
Zeba M. Khan, RPh, PhD

CEO & Executive Director
Nancy S. Berg
Welcome New 2020-2021 Board Members

President-Elect (2020-2021)
Isao Kamae, MD, Dr PH

Director (2020-2023)
Eberechukwu Onukwugha, MS, PhD

Director (2020-2023)
Kalipso Chalkidou, MD, PhD

Director (2020-2023)
David Thompson, PhD

Treasurer (2020-2023)
Sean D. Sullivan, PhD
2019-2020 Achievements

Strategic Plan Update 2024

Scientific Priorities Initiative

Diversity and Inclusion
Virtual ISPOR 2020—Panel Gender Diversity

Invited Sessions (Plenaries)
- Gender Diverse: 100%

Submitted Sessions (IPs, WSs)
- Gender Diverse: 77%
- All Female: 11%
- All Male: 11%
Virtual ISPOR 2020 vs ISPOR 2019
Submitted Sessions Diversity (Issue Panels, Workshops)

ISPOR 2019
- Gender Diverse: 62%
- All Female: 10%
- All Male: 29%

Virtual ISPOR 2020
- Gender Diverse: 77%
- All Female: 11%
- All Male: 11%
ISPOR Scientific Priorities—A New Initiative

- To guide & inform ISPOR’s mission-critical activities
- To meet the evolving needs of healthcare decision makers
- Placing ISPOR to be proactive in shaping the future of HEOR
- What are the big ideas, new methods and new applications, where breakthrough HEOR can advance our science and our impact?
- Ambitious timeline: 2020
- Input sought from ISPOR membership groups
- Working group coordinated by ISPOR Chief Scientist
Our members are ISPOR;
ISPOR is the heart of HEOR;
& HEOR is the foundation
for improving healthcare decisions.
Thank you!
Update and Financial Report

CEO’s Report

Nancy S. Berg
CEO and Executive Director
ISPOR
Strategic Plan Update Emphasizes

- Scientific Priorities
- Engaging Members Globally
- Increasing Collaboration
- Making an Impact
ISPOR Offices
Lawrenceville (Princeton), NJ USA

- ISPOR is a not-for-profit education organization
- $16.7-million in net assets with $13.3 million liquid. Net assets, or reserves, are maintained to support investments or to help sustain membership activities during downtimes.
- Serving 10,000-plus members and 10,000-plus Chapter members living in 114 countries and more than 125 ISPOR groups
- ISPOR-owned office encompasses 18,000 square feet of space and houses the majority of staff
- Expenses well controlled
Financial Audit

• Larson Allen LP was hired as ISPOR’s Auditor in 2015.
• Audit reviews internal procedures and seeks to identify deficiencies in internal controls relating to financial reporting which are deemed material weaknesses.
• Audit Results
  – ISPOR is doing well financially
  – No material weaknesses noted during audit
  – No internal control letter to be issued
  – No audit adjustments
# 2019 Audit Financial Statements: Summary

<table>
<thead>
<tr>
<th></th>
<th>12/31/19 Audited Financial Statements</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REVENUE</strong></td>
<td>$17,604,789</td>
</tr>
<tr>
<td><strong>EXPENSES</strong></td>
<td>$15,038,046</td>
</tr>
<tr>
<td><strong>CHANGE IN NET ASSETS</strong> (Addition)</td>
<td>$ 2,566,743</td>
</tr>
<tr>
<td><strong>NET ASSETS 12.31.19</strong></td>
<td>$17,949,965</td>
</tr>
</tbody>
</table>
## Income & Expenses

<table>
<thead>
<tr>
<th>Year</th>
<th>Income</th>
<th>Expenses</th>
<th>Net</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1997</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Net Assets
December 31, 2019 Assets & Liabilities

**Assets**
- Cash & Cash Equivalents: 10%
- Investments: 4%
- Property & Improvements: 4%
- Furniture & Fixtures: 2%
- Receivables: 4%
- Total: 68%

**Liabilities & Net Assets**
- Accounts Payable: 9%
- Accrued Expenses: 1%
- Deferred Revenue: 2%
- Other: 0%
- Net Assets: 88%
ISPOR, HEOR
...and COVID-19
The Future…

Virtual, Live, & Hybrid Events

Publications Opportunities

Value in Health

More Virtual Offerings for Training & Education

HEOR Role in Addressing COVID-19

Digital Transformation

Communicating HEOR’s Importance

Innovation in HEOR

Improving Healthcare Decisions

ISPOR Reports

Value in Health

Innovation in HEOR

Improving Healthcare Decisions
Publications Reports

Editors-in-Chief Remarks
Highlights

Themed Sections

2019
Evolution of EuroQol
Back to the Future (20th Anniversary Issue)
Curative Therapies

2020
HTA Around the World
Value-Based Contracting
Precision Medicine
Health Preferences Research

Annual Submissions

2018 = 1046
2019 = 1167
2020 = 445 (data as of 5/13/20; on track to exceed 1200 papers)

Key Statistics

Impact Factor: **5.037**
Rejection Rate: **82%** (nearly 72% are rejected without external peer review)
Value in Health Regional Issues

Presented by:
Manuel Espinoza, MD, MSc, PhD
Editor-in-Chief
Highlights

New Editorial Structure

Implemented in January 2020

- Overarching Editor-in-Chief
- Deputy Editors (1 for each region)
- Associate Editors (5 for each region)

Annual Submissions

<table>
<thead>
<tr>
<th>Region</th>
<th>2018</th>
<th>2019</th>
<th>2020 (as of 5/13/20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Totals:</td>
<td>183</td>
<td>200</td>
<td>95</td>
</tr>
<tr>
<td>Asia</td>
<td>67</td>
<td>84</td>
<td>46</td>
</tr>
<tr>
<td>CEEWAA</td>
<td>51</td>
<td>46</td>
<td>26</td>
</tr>
<tr>
<td>Latin America</td>
<td>65</td>
<td>70</td>
<td>23</td>
</tr>
</tbody>
</table>

2019 Rejection Rate: 57.1%

Themed Section

COVID-19: Case Studies from the Region [Editors to invite at least 1 study from each region]
Value & Outcomes Spotlight

Presented by:
David Thompson, PhD
Editor-in-Chief
Highlights

COVID-19 Coverage in March/April 2020 Issue

• Letter From the Editor: ISPOR in the Time of Corona
• From the President: COVID-19—A Call to Action for Health Economics and Outcomes Researchers
• Special Feature: The COVID-19 Virus in Wuhan, China: A Personal Story
• Q&A: Christian Lindmeier (WHO Spokesperson) and Mirjam Kretzschmar, PhD (Infectious Disease Modeler, University Medical Centre Utrecht)

2020 Feature Articles

• New Digital Healthcare Ecosystem (January/February)
• The State of Health Technology Assessment (March/April)
• Innovative Pricing Models (May/June)
• Behavioral Economics (July/August)
• Current State of Real-World Evidence (September/October)
• Deep Dive Into Stakeholder Perspectives (November/December)

New Editor-in-Chief

• Appointment of new Editor to begin on July 1, 2020
• I would like to personally thank ISPOR and all readers of Value & Outcomes Spotlight for their support during my tenure
Thank you
Member Discussion
Adjournment
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.

ISPOR’s community of more than 20,000 individual and chapter members from 120+ countries includes a wide variety of healthcare stakeholders, including researchers, academicians, regulators and assessors, public and private payers, healthcare providers, industry, and patient representatives. The Society’s leadership has served as an unbiased resource and catalyst for innovation in the field for more than 20 years.

www.ispor.org